All In Biotech

Drug Trial Radar · NCT05914077

Aspiration of Duodenopancreatic Juice After Secretin Stimulation vs Endoscopic Aspiration for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia.

Aspiration of Duodenopancreatic Juice After Secretin Stimulation (ADPJ-secr-) vs Endoscopic Aspiration (EUS-FNA) for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia (IPMN).

Last checked: Nov 19, 2026Latest source record: Sep 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

140

Planned (sponsor's estimate)

Start

Sep 13, 2023

Primary completion

Jan 2025

Study completion Jan 2025

Sponsor

Lead sponsor
Fundacion Clinic per a la Recerca BiomédicaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to evaluate aspiration of duodenopancreatic juice after secretin stimulation (ADPJ-secr)versus endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for molecular analysis of intraductal papillary mucinous intraductal neoplasia.

Conditions

  • Intraductal Papillary Mucinous Neoplasm of Pancreas

Interventions

  • SecretinDrug

    Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure.

  • Endoscopic aspirationProcedure

    Endoscopic aspiration of duodenopancreatic juice after secretin stimulation

  • Endoscopic ultrasound-guided fine needle aspirationProcedure

    Endoscopic ultrasound-guided fine needle aspiration of intraductal papillary mucinous intraductal neoplasia (IPMN).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with IPMN with GNAS and KRAS mutations in intracystic fluid obtained by EUS-FNA versus pancreatic juice obtained by ADPJ-secr after both techniques.Time frame: Through study completion, an average of 30 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Clínic de Barcelona

    Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.